Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $59.9 million.

  • Amphastar Pharmaceuticals' Short-term Investments rose 268.78% to $59.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.9 million, marking a year-over-year increase of 268.78%. This contributed to the annual value of $70.0 million for FY2024, which is 3775.13% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Short-term Investments of $59.9 million as of Q3 2025, which was up 268.78% from $44.1 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Short-term Investments ranged from a high of $112.5 million in Q4 2023 and a low of $8.0 million during Q3 2021
  • Moreover, its 5-year median value for Short-term Investments was $26.8 million (2022), whereas its average is $37.3 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Short-term Investments skyrocketed by 47216.23% in 2023 and then plummeted by 3880.46% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Short-term Investments (Quarter) stood at $10.3 million in 2021, then soared by 90.54% to $19.7 million in 2022, then skyrocketed by 472.16% to $112.5 million in 2023, then tumbled by 37.75% to $70.0 million in 2024, then decreased by 14.41% to $59.9 million in 2025.
  • Its last three reported values are $59.9 million in Q3 2025, $44.1 million for Q2 2025, and $54.1 million during Q1 2025.